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Introduction: Lung cancers can display immune cell infiltration
although the role of an adaptive immune response in disease patho-
genesis is unknown. To investigate the possibility of a functional
humoral response to the tumor, we surveyed histologic sections from
non-small cell lung cancer (NSCLC) tumors for germinal centers
(GCs) and assessed whether there was an association between the
presence of GCs and tumor stage.
Methods: Tumor sections from 91 patients with all stages of
NSCLC were examined by a pathologist blinded to clinical data.
GCs were identified by hematoxylin and eosin staining patterns and
confirmed by immunohistochemical staining for B-cell markers,
BCL-6 and CD21. The distribution of GCs within the tumor or the
tumor margin was recorded. Statistical analysis was performed to
evaluate the association between stage and presence of GCs.
Results: Thirty-five percent of all tumors evaluated contained GCs,
and sections evaluated by immunohistochemistry showed positive
staining for both B-cell markers. GCs were seen both within the
tumor and the tumor margin, consistent with an immune response to
antigen stimulation. Patients with stage I NSCLC had a higher
prevalence of intratumoral GCs than patients with stages II to IV
(Cochran-Armitage Trend Test p  0.02011). There was no asso-
ciation of stage with GCs in the tumor margin.
Conclusions: Intratumoral GCs are associated with early-stage
NSCLC. Further characterization of intratumoral GCs may lead to
new diagnostic and therapeutic strategies based on manipulation of
the adaptive immune response.
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(J Thorac Oncol. 2011;6: 1687–1690)
Lung cancer is a significant public health issue and is themost common cancer in both men and women. Most
patients present with advanced-stage disease when treat-
ment options are limited, and overall 5-year survival is less
than 15%. There is, however, a group of individuals who
have early-stage disease at presentation. Although these
patients are treated with surgical resection, up to 40% still
develop recurrence.1 A better understanding of the factors
that contribute to the absence of metastasis in select
patients may lead to more effective diagnostic and thera-
peutic approaches.
Tumor growth and metastasis reflect a dynamic,
multidimensional relationship between cancer cells and
host cells, including stromal, endothelial, and immune
cells.2,3 Tumors can be infiltrated with many types of
lymphocytes, some that may foster and others that may
inhibit tumor progression.4 Germinal centers (GCs) are
organized lymphoid structures important to the adaptive
immune response. They are well-defined loci of B cells, T
cells, and dendritic cells, in which B cells proliferate and
undergo differentiation, affinity maturation, and somatic
hypermutation.5 GCs are normally found in secondary
lymphoid organs such as the spleen and lymph nodes but
can develop as tertiary lymphoid structures in other loca-
tions, including tumors. Tumoral GCs have been reported
in breast cancer,6–9 germ cell cancers,10 non-small cell
lung cancer (NSCLC),11 and colon cancer.12
Although GCs are formed in response to antigen
stimulation, the biologic mechanisms for the development
of intratumoral GCs and their influence on disease course
are not well defined. In this study, we have used histology
and immunohistochemistry (IHC) for the GC B-cell mark-
ers, BCL-6, involved in GC B-cell function and the im-
mune response, and CD21, a marker expressed on mature
B-cells,13–16 to assess the presence of GCs in lung cancer
tissue, testing the hypothesis that the presence of GCs
within tumors is evidence of an adaptive immune response
that limits tumor progression in some patients. If this were
true, we would therefore expect an association between the
presence of tumoral GCs and cancer stage. We addressed
this hypothesis by histologic and IHC analysis of tumors
from patients with all stages of NSCLC. Our results
indicate an increased frequency of intratumoral GCs in
early-stage NSCLC.
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METHODS
Patient Selection
From our tumor registry, we selected 91 sequential
patients each of whom had a new diagnosis of NSCLC and a
pathologic specimen of the tumor. Eighty-five specimens
(93%) were from surgically resected tumors, and 6 specimens
were obtained from transbronchial biopsies (7%). There were
51 men and 40 women with a mean age of 65 years (range
28–81 years). Patient demographics are listed in Table 1.
This study was approved by our institutional review board.
Pathological Review
A single pathologist (R.C.B.) reviewed all slides for the
presence of GCs. GCs were identified on hematoxylin and
eosin (HE)-stained slides by the presence of a well-defined
follicle, with a follicular center containing a mixture of
immunoblasts, lymphocytes, tingible body macrophages, and
follicular dendritic cells. The location of the GC was defined
as peritumoral if it was outside the tumor mass, that is, there
was no tumor between the GC and surrounding nonneoplastic
lung. GCs were defined as intratumoral if it was within the
tumor mass; that is, there was tumor surrounding the GC on
all sides.
The pathologist had no access to clinical data and
recorded the presence or absence of GCs within the tumor
center (intratumoral) or at the margin (periphery) of the
tumor. Between one and five HE-stained slides were pre-
pared from the tumor blocks for each patient and multiple
sections, and fields per slide were evaluated (mean slides
per tumor  2.75, median slides per tumor  3.0; mean
number of sections per tumor  4.33, median number of
sections per tumor  4.0). IHC for BCL-6 and CD21 was
also performed for confirmation of GCs of randomly se-
lected cases with intratumoral GCs only, and in randomly
selected cases with both intratumoral GCs and peritumoral
GCs, and these were also reviewed by the pathologist. IHC
staining for both markers was recorded as positive or
negative.
Immunohistochemistry
IHC was performed using an anti-BCL-6 antibody
(M7211, Dako, Copenhagen, Denmark), diluted 1:10, or an
anti-CD21 antibody (Dako M0784), diluted 1:50. Antibody
incubation was carried out for 45 minutes at room tempera-
ture. Antigen retrieval was done by incubating slides for 20
minutes at 100°C with Dako Target Retrieval Solution, either
at pH 9.0 (Dako S2367) for BCL-6 or at pH 6.1 (Dako S1699)
for CD21. The slides were then incubated for 30 minutes with
the peroxidase-conjugated detection reagent Envision Plus
(Dako K4061) for 5 minutes with the substrate DAB (Dako
K3468) and for 30 seconds with the counterstain, hematoxylin.
Statistical Analysis
Exact tests, including Fisher’s exact test and the Coch-
ran-Armitage Trend test, were used to determine the associ-
ation between GCs and stage.
RESULTS
Distribution of GCs
An intratumoral GC stained with HE, and subjected to
IHC with antibodies to BCL-6 and CD21, is shown in Figure
1. The tissues from 35% (n  32) of all patients examined in
this study contained GCs either within the tumor center or at
the tumor margin. Approximately 9% (n  8) of all patients
had intratumoral GCs, and 30% (n  27) of all patients had
GCs in the tumor margin. Only 3% (n  3) of tumors had
both intratumoral GCs and GCs at the tumor margin. All GCs
examined by IHC showed positive staining for both BCL-6
and CD21, consistent with antigenic stimulation and B-cell
maturation. The number of GCs in the positive cases ranged
from 1 to 3 per 4 objective low-power field (15.9 mm2)
down to a single GC in the tumor sections examined with HE.
TABLE 1. Patient Demographics
Intratumoral Germinal
Centers
Not Present Present
Average age, yr (range) 64.4 (28–81) 70.0 (65–79)
Gender (frequency)
Male 47 4
Female 36 4
Histology (frequency)
Adenocarcinoma 48 5
Squamous cell carcinoma 22 2
Large cell carcinoma 6 1
Bronchioloalveolar carcinoma 1 0
NSCLC—not specified 6 0
NSCLC, non-small cell lung cancer.
FIGURE 1. A and B, A germinal center in a tumor section
from a patient with non-small cell lung cancer was stained
with hematoxylin and eosin. C and D, The same section was
subjected to immunohistochemistry using antibodies to
BCL-6 and CD21, respectively. Magnification was 40 in A
and 200 in B, C, and D.
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Association of Stage with GCs
There was a strong association between stage and the
presence of intratumoral GCs (Table 2). By stage, 16% of
stage I patients (7 of 43) had tumors with intratumoral GCs
present in the examined sections, versus 8% of stage II
patients (1 of 13) and none of the stage III (n  27) or
stage IV (n  8) patients (Cochran-Armitage Trend Test
p  0.02011).
There was no association of NSCLC stage with the
presence of GCs at the tumor margins. Tumor margin GCs
were present in 29% of stage I (12 of 42), 42% of stage II (5
of 12), 35% of stage III (9 of 26), and 14% of stage IV (1 of
7) patients (Cochran-Armitage Trend Test, p  0.999).
Intratumoral GCs and Recurrence in Early-
Stage I Disease
Seven stage I patients with intratumoral GCs have been
followed up for a mean of 21 months (range 12–32 months).
Only one of these seven patients (14%) developed metastasis,
diagnosed 8 months after presentation. This patient remains
alive 24 months after initial diagnosis. Thirty-six stage I
patients with no intratumoral GCs have been followed up for
a mean of 24 months (range 7–34 months). In contrast to the
patients whose tumors did have GCs, 8 of the 36 patients
(22%) with no intratumoral GCs developed metastasis. Me-
tastasis was diagnosed at an average of 10 months (range
4–17 months) after initial diagnosis. Three of these eight
patients (37.5%) died at a mean of 16 months after diagnosis.
DISCUSSION
The results of this study indicate that the presence of
intratumoral GCs is associated with early-stage NSCLC and
suggest that those patients whose tumors contain these struc-
tures may have a lower rate of recurrence. A previous study
by Dieu-Nosjean et al.11 also demonstrated the presence of
GCs in NSCLC. In that study, GCs were described as
components of tumor-induced, bronchus-associated lym-
phoid tissue (T-BALT). The density of mature dendritic
cells (DC-Lamp) that home exclusively to T-BALT was
found to be a strong prognostic indicator of disease-free
survival. In referring to that study, Page`s et al.12 stated that
T-BALT is “adjacent” to the tumor area in NSCLC. In this
study, we found GCs present in the tumor margin and
intratumorally, but only the intratumoral GCs correlated
with early-stage disease.
The association of GCs with both early-stage NSCLC
and low rates of recurrence suggests that in some patients, the
tumor microenvironment allows the formation of tertiary
lymphoid tissue, and the GCs may be the site of an adaptive
immune response that plays a role in limiting tumor growth
and metastasis. However, the nature of the tumor antigens
and other factors promoting GC formation and activity,
including mechanisms required for an effective antitumor
immune response, remain unknown. Although the study by
Dieu-Nosjean et al.11 found no association of survival with
tumoral B or T lymphocytes, it did not address the possibility
that subsets of lymphocytes, such as tumor antigen-specific
mature B cells, play a role in prolonging survival. Analysis of
antibodies produced by B cells within GCs in both breast and
germ cell tumors demonstrates the occurrence of an oligo-
clonal expansion of a B-cell repertoire that seems to be driven
by tumor antigens.6–10 A scenario in which locally produced
antibodies are functionally active is an intriguing possibility
that requires further exploration.
Autoantibodies to tumor antigens are commonly found
in patients with cancer but it is not known whether they can
alter the course of disease, and if so by what mechanism. The
effectiveness of the humoral response may relate to antibody
affinity or abundance, as recombinant monoclonal antibodies
with at least partial efficacy have been used for cancer
therapy. The possibility of developing an antimetastasis vac-
cine was demonstrated in a mouse melanoma model. Passive
immunization of mice to the tumor-associated antigen, gp75,
was protective against subsequent challenge with B16 mela-
noma cells.17 This finding suggests the possibility that auto-
antibodies that inhibit metastasis may be produced in select
patients. Indeed, we previously reported on autoantibodies to
complement factor H (CFH) that are present in the sera of
early-stage NSCLC patients at a significantly higher fre-
quency than in patients with metastatic disease.18 Because
CFH protects normal and cancer cells from complement
attack, autoantibodies to tumor cell–expressed CFH may
function by increasing the susceptibility of tumor cells to
complement lysis. It still remains unclear whether this auto-
antibody is a biomarker of early-stage disease or whether it
has functional consequences. Its potential mechanisms of
action are under investigation.
The presence of GCs in early-stage NSCLC is consis-
tent with an in situ immune response driven by tumor anti-
gens. At present, our study involves only a limited number of
patients. Nevertheless, the finding that stage I tumors con-
taining GCs have a low rate of recurrence suggests that some
patients with lung cancer may mount an effective humoral
response against their own tumors. In these patients, the
particular combination of stromal cells, immune cells, and
soluble factors that comprise the tumor microenvironment
might favor the development of tertiary lymphoid tissue in
response to cancer cell antigens. Alternatively, or in addition,
cancer cell antigens expressed in the tumors of some patients
might provoke especially strong immune responses. In addi-
tion to the antigen-induced humoral response, an effective
defense against tumors would likely include other aspects of
the innate and adaptive immune responses, including activa-
TABLE 2. Association of Intratumoral Germinal Centers
with Stage of NSCLC
Stage
Germinal Centers
Not Present, n (%) Present, n (%) Total Patients
I 36 (84) 7 (16) 43
II 12 (92) 1 (8) 13
III 27 (100) 0 27
IV 8 (100) 0 8
NSCLC, non-small cell lung cancer.
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tion of cellular immunity. Further characterization of the
humoral response to cancer in patients with a nonmetastatic
phenotype may lead to the development of new markers for
staging and to new strategies for therapeutic intervention.
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